Peptide · Modulator of sequestosome-1 (p62) ZZ domain (SQSTM1) · developed by Soligenix
Dusquetide is a synthetic five-amino-acid peptide, an innate defense regulator, that binds the ZZ domain of sequestosome-1 (p62) and activates innate immune signaling through pathways such as MAPK p38 and CCAAT-enhancer-binding protein. It is studied in oral mucositis, oral cavity and oropharyngeal squamous cell carcinoma, and Behçet disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03237325 | Phase 3 | Squamous Cell Carcinoma of the Oral Cavity and Oropharynx | Completed | SNGX |
| NCT06386744 | Phase 2 | Behçet Disease | Completed | SNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Behçet DiseaseOral MucositisSquamous Cell Carcinoma of the Oral Cavity and Oropharynx
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNGX page.
See SNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNGX catalysts and pipeline →